It sure appears that now is the time where the curtain will be pulled back on the below efforts.The coming weeks and months should be more than interesting to say the least.
Press Release Source: Cannabis Science, Inc. On Tuesday May 24, 2011, 3:01 pm EDT
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.ob - News), a US biotech company developing pharmaceutical cannabis products, is pleased to announce negotiations with several commercialization groups to bring its anti-cancer cannabis formulations to the public as soon as possible. This collection of public data will be a major contribution to the body of evidence that will guide our Investigative New Drug Applications to the FDA for critical ailments such as cancer.
Cancer is our number one target based on our acquisition of physician documented positive treatment results. Beyond the well-known palliative options that cannabis provides for patients suffering from cancer and the side effects of the standard treatments, there has been a worldwide explosion of scientific studies demonstrating the ability of cannabinoids to kill cancer cells in animals and tissue culture. Additionally, patients have initiated personal experimentation in medical marijuana states. Currently, the Company, in collaboration with the Phoenix Tears Foundation (PhoenixTearsFoundation.com), is aware of multiple patients involved in a cannabis-based self-treatment regimen designed to cease cancer progression, improve quality of life through increased sleep and nutrition intake, and in a number of cases put patients in remission.
It is now clear that a standardized, well-profiled, and safe cannabis extract must be used for the treatment of this disease. Cannabis Science has been actively working with other organizations – in the US and abroad – to meet this need not only on the dispensary level, but also in pursuing FDA approval. Our short-term goal is to coordinate clinical partnerships and patient care with a standardized Cannabis Science product line in Colorado, and to gather data that supports the use of cannabis extracts for this indication. Cancer drugs tend to be hugely expensive. It is a multi-billion dollar market. However, it is not clear how the current market size could be extrapolated into any valuation of cannabis products, which would cost far less.
The Company is also developing some creative new national and international educational programs about Cannabis Science for a variety of media. The focus will be on patient interactions, successful self-medication, pharmaceutical grade cannabis product development, quality control standardizations, successful anti-cancer cannabis treatments, as well as patient data retention nationally and internationally.
Press Release Source: Cannabis Science, Inc. On Wednesday July 27, 2011, 1:50 pm EDT
DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.ob - News), a US biotech company developing pharmaceutical cannabis products, is pleased to provide investor guidance on its previously announced Medicinal Cannabis Commercialization negotiations and current operational structures. Currently, Cannabis Science has some outstanding business opportunities in the final stages of closing. It anticipates announcing the first one within the next week. Some of these new deals are designed to bring its anti-cancer cannabis formulations and its other critical ailment formulations to the public through the FDA in the USA and more rapidly through other expanded markets around the world.
One of the larger deals the company expects to sign and announce within the next few days is a business relationship with a multi-million dollar pharmaceutical technology provider. Under the terms of the agreement, Cannabis Science will work closely with the technology provider to market and sell their co-branded products on an exclusive and non-exclusive basis with this new ground breaking technology in the Medical Cannabis industry. Cannabis Science sees this as an incredible opportunity to participate in an exciting growing technology company while at the same time advancing its medical marijuana medicine market and development.
The Company is in advanced stages of negotiations to contract for a joint-marketing program that will provide cancer patients with proprietary medical marijuana formulations for cancer treatment. According to the World Health Organization, 12 million cancer deaths are likely to occur worldwide by 2030. With the $47.7 billion cancer drug market projected to grow significantly over the coming decades, Cannabis Science is committed and focused on positioning itself as a key player in the medical cannabis cancer treatment sector.
Robert Melamede, Ph.D. and Cannabis Science CEO said, “We appreciate the dedication and patience that many of our investors have shown. We have been working diligently to provide a path in the complicated legal and regulatory environment that surrounds the medical cannabis industry that will benefit our shareholders and the countless people in need around the world who have been deprived of the health promoting benefits provided by this unique plant. These commercialization agreements will give us an opportunity to generate significant revenues for Cannabis Science We provide a further update and agreement details in the coming weeks as these commercial agreements are signed.”
*** In a few days we'll know alot more about the fruits of their labor. ***
AI
Market Data 
Markets 
